We aim for sustainable performance over time to benefit patients, employees, shareholders and society. Solid financial results and maintaining the trust of society underpin our ability to create value.
Walkway at the entrance of the Novartis Campus in Basel, Switzerland

Investors Event Calendar

View recent presentations and learn more about upcoming events.
June 04, 2023
ASCO Investor Event
Chicago, USA

Van Lacour, prostate cancer patient living in Natchez, Louisiana, who received a Novartis radioligand therapy

Novartis Annual Reporting Suite

Read and download our integrated report, annual regulatory filings, and other disclosures.

Doctor prescribing medication in Rwanda

Environmental, Social and Governance (ESG)

Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. We take bold steps to increase access to medicines, tackle complex global health challenges, and do our part as a responsible corporate citizen.

ESG Updates: May 03, 2023 (PDF 1.9 MB) | Feb 06, 2023 (PDF 0.9 MB) | Oct 31, 2022 (PDF 0.5 MB) | July 20, 2022 (PDF 0.4 MB)
Latest updates: Investor Update on Access & Sustainability (PDF 1.6 MB) | Novartis Enterprise Risk Management (PDF 0.2 MB)  | Materiality Assessment


We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics.



Pulse Updates

April 21, 2023

FDA approves Novartis Millburn facility for US commercial production of Pluvicto®

Read more

March 02, 2023

Novartis completes FDA filing for approval of Millburn facility to support Pluvicto® launch

Read more


January 09, 2023

Novartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023

Read more

December 16, 2021

Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease

Read more

Investor Relations Contacts

For questions about investor relations or the share registry, please contact our team.


Stay Up-to-Date

Stay connected to the latest news and information from Novartis.


Novartis AG
Lichtstrasse 35
CH-4056 Basel, Switzerland